Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity

Ronan Joseph Kelly, Colleen Darnell, Olivier Rixe

Research output: Contribution to journalArticle

Abstract

Recent studies have revealed a previously unsuspected degree of vascular specialization within the host tissue and a tumor's microenvironment. The "vascular zip code" has been used to describe the unique expression of cell-surface molecules found in each vascular bed. Characterization of tumor blood vessels includes selective overexpression of a heterogenous group of proteins such as proteases, integrins, growth factor receptors, and proteoglycans. The process of angiogenesis consists of a "true cytokine storm," requiring many molecular events and biological steps. Antiangiogenic drugs may target a single critical kinase pathway or may interact with several nonspecific molecular targets via a process termed extended spectrum kinase inhibition. The latter strategy may lead to an absence of selectivity and specificity and may result in enhanced toxicities. In this review, we discuss recent developments in the pathogenesis of commonly observed adverse events and summarize new strategies that may ultimately improve efficacy and limit toxicity.

Original languageEnglish (US)
Pages (from-to)635-642
Number of pages8
JournalCancer Journal
Volume16
Issue number6
DOIs
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

Blood Vessels
Phosphotransferases
Vascular Tissue Neoplasms
Critical Pathways
Tumor Microenvironment
Growth Factor Receptors
Proteoglycans
Integrins
Peptide Hydrolases
Therapeutics
Cytokines
Pharmaceutical Preparations
Proteins

Keywords

  • on/off target
  • selective
  • specific
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity. / Kelly, Ronan Joseph; Darnell, Colleen; Rixe, Olivier.

In: Cancer Journal, Vol. 16, No. 6, 11.2010, p. 635-642.

Research output: Contribution to journalArticle

Kelly, Ronan Joseph ; Darnell, Colleen ; Rixe, Olivier. / Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity. In: Cancer Journal. 2010 ; Vol. 16, No. 6. pp. 635-642.
@article{be5fe0a09e0d45fbbfc0758667bf50cd,
title = "Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity",
abstract = "Recent studies have revealed a previously unsuspected degree of vascular specialization within the host tissue and a tumor's microenvironment. The {"}vascular zip code{"} has been used to describe the unique expression of cell-surface molecules found in each vascular bed. Characterization of tumor blood vessels includes selective overexpression of a heterogenous group of proteins such as proteases, integrins, growth factor receptors, and proteoglycans. The process of angiogenesis consists of a {"}true cytokine storm,{"} requiring many molecular events and biological steps. Antiangiogenic drugs may target a single critical kinase pathway or may interact with several nonspecific molecular targets via a process termed extended spectrum kinase inhibition. The latter strategy may lead to an absence of selectivity and specificity and may result in enhanced toxicities. In this review, we discuss recent developments in the pathogenesis of commonly observed adverse events and summarize new strategies that may ultimately improve efficacy and limit toxicity.",
keywords = "on/off target, selective, specific, Vascular endothelial growth factor",
author = "Kelly, {Ronan Joseph} and Colleen Darnell and Olivier Rixe",
year = "2010",
month = "11",
doi = "10.1097/PPO.0b013e3181ff37cf",
language = "English (US)",
volume = "16",
pages = "635--642",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "0765-7846",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "6",

}

TY - JOUR

T1 - Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity

AU - Kelly, Ronan Joseph

AU - Darnell, Colleen

AU - Rixe, Olivier

PY - 2010/11

Y1 - 2010/11

N2 - Recent studies have revealed a previously unsuspected degree of vascular specialization within the host tissue and a tumor's microenvironment. The "vascular zip code" has been used to describe the unique expression of cell-surface molecules found in each vascular bed. Characterization of tumor blood vessels includes selective overexpression of a heterogenous group of proteins such as proteases, integrins, growth factor receptors, and proteoglycans. The process of angiogenesis consists of a "true cytokine storm," requiring many molecular events and biological steps. Antiangiogenic drugs may target a single critical kinase pathway or may interact with several nonspecific molecular targets via a process termed extended spectrum kinase inhibition. The latter strategy may lead to an absence of selectivity and specificity and may result in enhanced toxicities. In this review, we discuss recent developments in the pathogenesis of commonly observed adverse events and summarize new strategies that may ultimately improve efficacy and limit toxicity.

AB - Recent studies have revealed a previously unsuspected degree of vascular specialization within the host tissue and a tumor's microenvironment. The "vascular zip code" has been used to describe the unique expression of cell-surface molecules found in each vascular bed. Characterization of tumor blood vessels includes selective overexpression of a heterogenous group of proteins such as proteases, integrins, growth factor receptors, and proteoglycans. The process of angiogenesis consists of a "true cytokine storm," requiring many molecular events and biological steps. Antiangiogenic drugs may target a single critical kinase pathway or may interact with several nonspecific molecular targets via a process termed extended spectrum kinase inhibition. The latter strategy may lead to an absence of selectivity and specificity and may result in enhanced toxicities. In this review, we discuss recent developments in the pathogenesis of commonly observed adverse events and summarize new strategies that may ultimately improve efficacy and limit toxicity.

KW - on/off target

KW - selective

KW - specific

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=78650506417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650506417&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e3181ff37cf

DO - 10.1097/PPO.0b013e3181ff37cf

M3 - Article

C2 - 21131797

AN - SCOPUS:78650506417

VL - 16

SP - 635

EP - 642

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 0765-7846

IS - 6

ER -